Crossmark

Quantification of radiation retinopathy after beam proton irradiation in centrally located choroidal melanoma

Crossref DOI link: https://doi.org/10.1007/s00417-018-4036-3

Published Online: 2018-06-12

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Busch, Catharina

Löwen, Julia

Pilger, Daniel

Seibel, Ira

Heufelder, Jens

Joussen, Antonia M.
License Information

Text and Data Mining valid from 2018-06-12
More Information

Article History

Received: 18 February 2018

Revised: 12 May 2018

Accepted: 2 June 2018

First Online: 12 June 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: For this type of study, formal consent is not required.

: All authors declare to have no proprietary interest.

: C.B.: payment for development of educational presentations (Pharm-Allergan GmbH, Frankfurt am Main, Germany); I.S.: payment for development of educational presentations (Novartis Pharma GmbH, Nürnberg, Germany, Pharm-Allergan GmbH, Frankfurt am Main, Germany, Bayer AG, Leverkusen, Germany); J.H.: none, A.M.J.: payment for development of educational presentations (Novartis Pharma GmbH, Nürnberg, Germany) and travel/accommodations/meeting expenses (Novartis Pharma GmbH, Nürnberg, Germany, Alcon Pharma GmbH Freiburg im Breisgau, Germany, and Pharm-Allergan GmbH, Frankfurt am Main, Germany).